Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DMACNASDAQ:FWPOTCMKTS:IGXTNASDAQ:PLXPNASDAQ:SEEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMACDiaMedica Therapeutics$2.53+3.3%$2.80$1.53▼$4.75$96.03M1.6940,918 shs6,852 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/AIGXTIntelGenx Technologies$0.17+13.3%$0.16$0.09▼$0.22$29.69M2.4396,160 shs149,612 shsPLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shsSEELSeelos Therapeutics$0.29-6.5%$0.72$0.28▼$49.80$3.91M1.88429,480 shs363,408 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMACDiaMedica Therapeutics+1.24%-5.77%-8.58%-8.58%+60.13%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%IGXTIntelGenx Technologies-8.48%-6.25%-11.00%+6.16%-18.48%PLXPPLx Pharma0.00%0.00%0.00%0.00%-98.60%SEELSeelos Therapeutics-7.98%-9.34%-39.06%-71.33%-98.50%It’s now possible to know the win rate of every trade… BEFORE you take it! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here <<MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDMACDiaMedica Therapeutics2.0428 of 5 stars3.54.00.00.03.30.00.0FWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/AN/AN/AN/ASEELSeelos Therapeutics1.9737 of 5 stars3.24.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMACDiaMedica Therapeutics3.00Buy$7.00176.68% UpsideFWPForward Pharma A/SN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/ASEELSeelos Therapeutics2.33Hold$70.0024,409.80% UpsideCurrent Analyst RatingsLatest DMAC, FWP, IGXT, SEEL, and PLXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AFWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/AIGXTIntelGenx Technologies$1.04M28.55N/AN/A($0.07) per share-2.43PLXPPLx Pharma$4.54M0.00N/AN/A$1.30 per share0.00SEELSeelos Therapeutics$2.20M1.78N/AN/A($3.42) per share-0.08Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMACDiaMedica Therapeutics-$19.38M-$0.62N/A∞N/AN/A-40.07%-37.90%5/20/2024 (Estimated)FWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/AIGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/A-955.44%N/A-128.18%N/APLXPPLx Pharma-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/ASEELSeelos Therapeutics-$37.88MN/A0.00∞N/A-1,719.56%N/A-517.23%5/20/2024 (Estimated)Latest DMAC, FWP, IGXT, SEEL, and PLXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IGXTIntelGenx TechnologiesN/A-$0.02-$0.02-$0.03N/A$0.43 million 3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/ASEELSeelos TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMACDiaMedica TherapeuticsN/A19.2719.27FWPForward Pharma A/SN/A18.43N/AIGXTIntelGenx TechnologiesN/A0.410.40PLXPPLx PharmaN/A4.794.28SEELSeelos TherapeuticsN/A0.140.14OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMACDiaMedica Therapeutics10.12%FWPForward Pharma A/S12.57%IGXTIntelGenx TechnologiesN/APLXPPLx Pharma21.19%SEELSeelos Therapeutics23.37%Insider OwnershipCompanyInsider OwnershipDMACDiaMedica Therapeutics7.20%FWPForward Pharma A/S71.47%IGXTIntelGenx Technologies42.05%PLXPPLx Pharma8.95%SEELSeelos Therapeutics5.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableIGXTIntelGenx Technologies4174.66 million101.21 millionNot OptionablePLXPPLx Pharma1629.14 million26.53 millionNot OptionableSEELSeelos Therapeutics1513.68 million12.94 millionOptionableDMAC, FWP, IGXT, SEEL, and PLXP HeadlinesSourceHeadlineInfusion therapy SLS-005 fails to slow ALS progression in trialalsnewstoday.com - April 4 at 11:49 PMSEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023investorplace.com - March 22 at 3:12 PMALS trial flops but Seelos sees potential for efficacythepharmaletter.com - March 21 at 6:27 PMSLS-005 may slow ALS progression for patients not on Relyvrio: Studyalsnewstoday.com - March 20 at 5:39 PMOptimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Resultsmarkets.businessinsider.com - March 20 at 5:39 PMSeelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In Endpointsmarkets.businessinsider.com - March 19 at 10:34 PMSeelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpointsmarketwatch.com - March 19 at 10:34 PMNasdaq Down 100 Points; US Housing Starts Surge In Februarymarkets.businessinsider.com - March 19 at 5:34 PMCNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Whymsn.com - March 19 at 5:34 PMSeelos says ALS treatment fails in mid-stage studyreuters.com - March 19 at 5:34 PMUPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage studyfinance.yahoo.com - March 19 at 5:34 PMSeelos falls as lead drug fails in ALS trialmsn.com - March 19 at 9:35 AMSeelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)prnewswire.com - March 19 at 8:15 AMFrom LSD to healing minds: Where are we standing in psychedelic drug development?labiotech.eu - March 13 at 1:26 PMSeelos Therapeutics files patent for treatment of neurodegenerative diseases using viral vectors encoding peptidespharmaceutical-technology.com - March 6 at 7:00 PMSeelos Therapeutics Inc.thestreet.com - February 9 at 11:53 AMSeelos Therapeutics, Inc. (SEEL)ca.finance.yahoo.com - February 1 at 12:51 PMSeelos Therapeutics Issues Common Warrants to Investorsmsn.com - January 31 at 3:52 PMSeelos Therapeutics Strikes $4M Direct Offering Dealmsn.com - January 31 at 10:18 AMSeelos Therapeutics Announces $4 Mln Direct Offering And Private Placement Of Sharesmarkets.businessinsider.com - January 26 at 9:42 PMSeelos Therapeutics Shares Hit 52-Week Low After Direct Offering Pricesmarketwatch.com - January 26 at 9:42 PMSeelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - January 26 at 9:42 PMSeelos Therapeutics Says Received Minutes From End Of Phase II Meeting With FDAmarkets.businessinsider.com - January 22 at 10:13 AMSeelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002finance.yahoo.com - January 22 at 10:13 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsDiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Forward Pharma A/SNASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.IntelGenx TechnologiesOTCMKTS:IGXTIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.PLx PharmaNASDAQ:PLXPPLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.Seelos TherapeuticsNASDAQ:SEELSeelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.